Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: Dependence on stent implantation and antithrombotic medication

24Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background. The plasmin activation system is involved in the development of restenosis after percutaneous coronary interventions (PCI). Conflicting data exist concerning the role of plasminogen activator inhibitor-1 (PAI-1) and its predictive value for restenosis. Objectives: To evaluate the fibrinolytic response to injury after PCI with or without stent implantation on different antithrombotic medications and its relation to late restenosis. Patients and methods: Eighty consecutive patients with successful PCI without (balloon only; n = 37) or with stent implantation (stent; n = 43) on different antithrombotic regimes (balloon only, aspirin; stent, aspirin/coumadin/dipyridamole vs. aspirin/ticlopidine). Blood samples were taken at baseline and up to 7 days after PCI and PAI-1 active antigen and tissue plasminogen activator (t-PA) antigen were determined. Restenosis was angiographically determined after 6 months. Results: PCI increased both t-PA and PAI-1 levels (P < 0.001), with a significant prolonged and pronounced increase in stent vs. balloon-only patients (P < 0.05). Restenosis (stent 26%; balloon 38%) was significantly correlated to an attenuated PAI-1 increase after 24 h in the ticlopidine group (P = 0.007; restenosis, relative Δ PAI-1 + 50 ± 28%; non-restenosis, + 139 ± 50%), but not in the coumadin group. In the balloon-only group late restenosis (ISR) was associated with a trend for an augmented PAI-1 increase after 24 h. Conclusions: Coronary stent implantation significantly increases t-PA and PAI-1 plasma levels up to 1 week compared with balloon angioplasty alone. ISR in ticlopidine-treated patients was associated with an attenuated early PAI-1 active antigen increase. A less than 50% increase 24 h after stent implantation under ticlopidine treatment may identify patients at risk for the development of ISR. © 2005 International Society on Thrombosis and Haemostasis.

Author supplied keywords

Cite

CITATION STYLE

APA

Christ, G., Nikfardjam, M., Huber-Beckmann, R., Gottsauner-Wolf, M., Glogar, D., Binder, B. R., … Huber, K. (2005, February). Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: Dependence on stent implantation and antithrombotic medication. Journal of Thrombosis and Haemostasis. https://doi.org/10.1111/j.1538-7836.2004.01062.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free